Nidan Laboratories and Healthcare's basic earnings per share (Basic EPS) for the
six
months ended in Mar. 2025 was ₹0.63.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2025 was ₹1.42.
During the past 7 years, Nidan Laboratories and Healthcare's highest 3-Year average EPS without NRI Growth Rate was 152.60% per year. The lowest was -18.50% per year. And the median was 28.55% per year.
Nidan Laboratories and Healthcare (NSE:NIDAN) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Nidan Laboratories and Healthcare EPS (Basic) Related Terms
Nidan Laboratories and Healthcare EPS (Basic) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nidan Laboratories and Healthcare EPS (Basic) Chart
Nidan Laboratories and Healthcare EPS (Basic) Calculation
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹1.42
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nidan Laboratories and Healthcare (NSE:NIDAN) has a EPS (Basic) of ₹1.42 as of Mar. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Nidan Laboratories and Healthcare and its competitors.
Is Nidan Laboratories and Healthcare's EPS (Basic) too high?
Nidan Laboratories and Healthcare's current EPS (Basic) is ₹1.42. Overall, Nidan Laboratories and Healthcare has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nidan Laboratories and Healthcare's EPS (Basic) compare to TMO and DHR?
Nidan Laboratories and Healthcare's EPS (Basic) of ₹1.42 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Diagnostics & Research company?
A good EPS (Basic) depends on the Medical Diagnostics & Research industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Nidan Laboratories and Healthcare and its competitors. Nidan Laboratories and Healthcare's current EPS (Basic) is ₹1.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nidan Laboratories and Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Nidan Laboratories and Healthcare (NSE:NIDAN) is currently considered Possible Value Trap. The stock's GF Value™ is ₹29.28, compared to a current price of ₹13.60 — trading 53.6% below its estimated fair value. The current EPS (Basic) is ₹1.42. Nidan Laboratories and Healthcare's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Nidan Laboratories and Healthcare (NSE:NIDAN), the current EPS (Basic) is ₹1.42 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nidan Laboratories and Healthcare (NSE:NIDAN) Overvalued in 2026?
Based on GuruFocus' analysis, Nidan Laboratories and Healthcare stock appears to be undervalued.
The current stock price of ₹13.60 is trading 53.6% below its estimated GF Value™ of ₹29.28.
GuruFocus considers Nidan Laboratories and Healthcare to be Possible Value Trap.
Key valuation signals for NSE:NIDAN:
EPS (Basic): ₹1.42
GF Value™: ₹29.28 vs. price of ₹13.60 (53.6% below fair value)
No single metric tells the full story. See the NSE:NIDAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nidan Laboratories and Healthcare Business Description
Nidan Laboratories and Healthcare Ltd offer diagnostic services including radiology, neurology, cardiology, dental as well as pathology services. The company provides pathology tests ranging from basic biochemistry and clinical pathology to cytogenetic and high-end molecular diagnostic tests, and radiology tests ranging from basic echocardiograms, X-Rays, and ultrasounds to radiology tests including computerized tomography scans, magnetic resonance imaging scans.
67GF Score
Get the complete analysis for NSE:NIDAN
EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NIDAN has been successfully added to your 
